P2RY12 and acute coronary syndrome: [2,3] The introduction of two additional oral P2Y12-inhibitors, prasugrel and ticagrelor, extended the armamentarium of this drug class in addition to clopidogrel, and further improved outcome in patients presenting with acute coronary syndrome (ACS).[4,5] Both substances have been adopted into European treatment guidelines, which both recommend the use of these novel P2Y12-inhibitors over clopidogrel for all patients presenting with ACS without overt contraindications.[6–8]